|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun JH, Luo Q, Liu LL and Song GB: Liver
cancer stem cell markers: Progression and therapeutic implications.
World J Gastroenterol. 22:3547–3557. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karakasiliotis I and Mavromara P:
Hepatocellular carcinoma: From hepatocyte to liver cancer stem
cell. Front Physiol. 6:1542015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grosse-Gehling P, Fargeas CA, Dittfeld C,
Garbe Y, Alison MR, Corbeil D and Kunz-Schughart LA: CD133 as a
biomarker for putative cancer stem cells in solid tumours:
Limitations, problems and challenges. J Pathol. 229:355–378. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suetsugu A, Nagaki M, Aoki H, Motohashi T,
Kunisada T and Moriwaki H: Characterization of CD133+
hepatocellular carcinoma cells as cancer stem/progenitor cells.
Biochem Biophys Res Commun. 351:820–824. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li B, McCrudden CM, Yuen HF, Xi X, Lyu P,
Chan KW, Zhang SD and Kwok HF: CD133 in brain tumor: The prognostic
factor. Oncotarget. 8:11144–11159. 2017.PubMed/NCBI
|
|
7
|
Okamoto K, Ninomiya I, Ohbatake Y, Hirose
A, Tsukada T, Nakanuma S, Sakai S, Kinoshita J, Makino I, Nakamura
K, et al: Expression status of CD44 and CD133 as a prognostic
marker in esophageal squamous cell carcinoma treated with
neoadjuvant chemotherapy followed by radical esophagectomy. Oncol
Rep. 36:3333–3342. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tu Z, Xie S, Xiong M, Liu Y, Yang X, Tembo
KM, Huang J, Hu W, Huang X, Pan S, et al: CXCR4 is involved in
CD133-induced EMT in non-small cell lung cancer. Int J Oncol.
50:505–514. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shmelkov SV, Butler JM, Hooper AT, Hormigo
A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et
al: CD133 expression is not restricted to stem cells, and both
CD133+ and CD133 metastatic colon cancer cells initiate
tumors. J Clin Invest. 118:2111–2120. 2008.PubMed/NCBI
|
|
10
|
Vander Griend DJ, Karthaus WL, Dalrymple
S, Meeker A, DeMarzo AM and Isaacs JT: The role of CD133 in normal
human prostate stem cells and malignant cancer-initiating cells.
Cancer Res. 68:9703–9711. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qin Q, Sun Y, Fei M, Zhang J, Jia Y, Gu M,
Xia R, Chen S and Deng A: Expression of putative stem marker nestin
and CD133 in advanced serous ovarian cancer. Neoplasma. 59:310–315.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jang JW, Song Y, Kim SH, Kim JS, Kim KM,
Choi EK, Kim J and Seo HR: CD133 confers cancer stem-like cell
properties by stabilizing EGFR-AKT signaling in hepatocellular
carcinoma. Cancer Lett. 389:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xi G, Li YD, Grahovac G, Rajaram V,
Wadhwani N, Pundy T, Mania-Farnell B, James CD and Tomita T:
Targeting CD133 improves chemotherapeutic efficacy of recurrent
pediatric pilocytic astrocytoma following prolonged chemotherapy.
Mol Cancer. 16:212017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma S, Lee TK, Zheng BJ, Chan KW and Guan
XY: CD133+ HCC cancer stem cells confer chemoresistance
by preferential expression of the Akt/PKB survival pathway.
Oncogene. 27:1749–1758. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Li H, Ge C, Li M, Zhao FY, Hou
HL, Zhu MX, Tian H, Zhang LX, Chen TY, et al: Inhibitory effects of
transcription factor Ikaros on the expression of liver cancer stem
cell marker CD133 in hepatocellular carcinoma. Oncotarget.
5:10621–10635. 2014.PubMed/NCBI
|
|
16
|
Guéritte-Voegelein F, Guénard D, Dubois J,
Wahl A and Potier P: Chemical and biological studies on Taxol
(Paclitaxel) and Taxotere (Docetaxel), new antineoplastic agents. J
Pharm Belg. 49:193–205. 1994.(In French). PubMed/NCBI
|
|
17
|
Seguin C, Kovacevich N and Voutsadakis IA:
Docetaxel-associated myalgia-arthralgia syndrome in patients with
breast cancer. Breast Cancer. 9:39–44. 2017.PubMed/NCBI
|
|
18
|
Belz J, Castilla-Ojo N, Sridhar S and
Kumar R: Radiosensitizing silica nanoparticles encapsulating
docetaxel for treatment of prostate cancer. Methods Mol Biol.
1530:403–409. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Albany C and Sonpavde G: Docetaxel for the
treatment of bladder cancer. Expert Opin Investig Drugs.
24:1657–1664. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dassen AE, Bernards N, Lemmens VE, van de
Wouw YA, Bosscha K, Creemers GJ and Pruijt HJ: Phase II study of
docetaxel, cisplatin and capecitabine as preoperative chemotherapy
in resectable gastric cancer. World J Gastrointest Surg. 8:706–712.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hami Z, Rezayat SM, Gilani K, Amini M and
Ghazi-Khansari M: In-vitro cytotoxicity and combination effects of
the docetaxel-conjugated and doxorubicin-conjugated poly(lactic
acid)-poly(ethylene glycol)-folate-based polymeric micelles in
human ovarian cancer cells. J Pharm Pharmacol. 69:151–160. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Posch D, Fuchs H, Kornek G, Grah A, Pammer
J, Aretin MB and Fuereder T: Docetaxel plus cetuximab biweekly is
an active regimen for the first-line treatment of patients with
recurrent/metastatic head and neck cancer. Sci Rep. 6:329462016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fukae M, Shiraishi Y, Hirota T, Sasaki Y,
Yamahashi M, Takayama K, Nakanishi Y and Ieiri I: Population
pharmacokinetic-pharmacodynamic modeling and model-based prediction
of docetaxel-induced neutropenia in Japanese patients with
non-small cell lung cancer. Cancer Chemother Pharmacol.
78:1013–1023. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu D, Tao W, Zhang H, Liu G, Wang T,
Zhang L, Zeng X and Mei L: Docetaxel (DTX)-loaded
polydopamine-modified TPGS-PLA nanoparticles as a targeted drug
delivery system for the treatment of liver cancer. Acta Biomater.
30:144–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li L, Tang F, Liu H, Liu T, Hao N, Chen D,
Teng X and He J: In vivo delivery of silica nanorattle encapsulated
docetaxel for liver cancer therapy with low toxicity and high
efficacy. ACS Nano. 4:6874–6882. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pu H, Zheng Q, Li H, Wu M, An J, Gui X, Li
T and Lu D: CUDR promotes liver cancer stem cell growth through
upregulating TERT and C-Myc. Oncotarget. 6:40775–40798. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Feng X, Zhu K, Liu J, Chen J, Tang J,
Liang Y, Jin R, Liang X and Cai X: The evaluative value of Sema3C
and MFN2 co-expression detected by immunohistochemistry for
prognosis in hepatocellular carcinoma patients after hepatectomy.
Onco Targets Ther. 9:3213–3221. 2016.PubMed/NCBI
|
|
28
|
Han TD, Shang DH and Tian Y: Docetaxel
enhances apoptosis and G2/M cell cycle arrest by suppressing
mitogen-activated protein kinase signaling in human renal clear
cell carcinoma. Genet Mol Res. 15:2016. View Article : Google Scholar :
|
|
29
|
He X, Li C, Wu X and Yang G: Docetaxel
inhibits the proliferation of non-small-cell lung cancer cells via
upregulation of microRNA-7 expression. Int J Clin Exp Pathol.
8:9072–9080. 2015.PubMed/NCBI
|
|
30
|
Geng CX, Zeng ZC, Wang JY, Xuan SY and Lin
CM: Docetaxel shows radiosensitization in human hepatocellular
carcinoma cells. World J Gastroenterol. 11:2990–2993. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Geng CX, Zeng ZC and Wang JY: Docetaxel
inhibits SMMC-7721 human hepatocellular carcinoma cells growth and
induces apoptosis. World J Gastroenterol. 9:696–700. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin HL, Liu TY, Chau GY, Lui WY and Chi
CW: Comparison of 2-methoxyestradiol-induced, docetaxel-induced,
and paclitaxel-induced apoptosis in hepatoma cells and its
correlation with reactive oxygen species. Cancer. 89:983–994. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yata Y, Xue F, Takahara T, Kudo H, Hirano
K, Yasumura S, Minemura M, Scanga AE and Sugiyama T: Docetaxel
inhibits progression of human hepatoma cell line in vitro and is
effective in advanced hepatocellular carcinoma. Hepatol Res.
40:304–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang L, Xu JF, Kang Q, Li AQ, Jin P, Wang
X, He YQ, Li N, Cheng T and Sheng JQ: Predictive value of stemness
factor Sox2 in gastric cancer is associated with tumor location and
stage. PLoS One. 12:e01691242017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Weina K and Utikal J: SOX2 and cancer:
Current research and its implications in the clinic. Clin Transl
Med. 3:192014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sodja E, Rijavec M, Koren A, Sadikov A,
Korošec P and Cufer T: The prognostic value of whole blood SOX2,
NANOG and OCT4 mRNA expression in advanced small-cell lung cancer.
Radiol Oncol. 50:188–196. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carrasco-Garcia E, Santos JC, Garcia I,
Brianti M, García-Puga M, Pedrazzoli J Jr, Matheu A and Ribeiro ML:
Paradoxical role of SOX2 in gastric cancer. Am J Cancer Res.
6:701–713. 2016.PubMed/NCBI
|
|
38
|
Zheng Y, Qin B, Li F, Xu S, Wang S and Li
L: Clinicopathological significance of Sox2 expression in patients
with breast cancer: A meta-analysis. Int J Clin Exp Med.
8:22382–22392. 2015.PubMed/NCBI
|
|
39
|
Kim BW, Cho H, Choi CH, Ylaya K, Chung JY,
Kim JH and Hewitt SM: Clinical significance of OCT4 and SOX2
protein expression in cervical cancer. BMC Cancer. 15:10152015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Du J, Li B, Fang Y, Liu Y, Wang Y, Li J,
Zhou W and Wang X: Overexpression of Class III β-tubulin, Sox2, and
nuclear Survivin is predictive of taxane resistance in patients
with stage III ovarian epithelial cancer. BMC Cancer. 15:5362015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun C, Sun L, Li Y, Kang X, Zhang S and
Liu Y: Sox2 expression predicts poor survival of hepatocellular
carcinoma patients and it promotes liver cancer cell invasion by
activating Slug. Med Oncol. 30:5032013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sharma VR, Gupta GK and Sharma AK, Batra
N, Sharma DK, Joshi A and Sharma AK: PI3K/Akt/mTOR Intracellular
Pathway and Breast Cancer: Factors, Mechanism and Regulation. Curr
Pharm Des. 23:1633–1638. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao Y, Xiao X, Zhang C, Yu W, Guo W, Zhang
Z, Li Z, Feng X, Hao J, Zhang K, et al: Melatonin synergizes the
chemotherapeutic effect of 5-fluorouracil in colon cancer by
suppressing PI3K/AKT and NF-κB/iNOS signaling pathways. J Pineal
Res. 62:2017. View Article : Google Scholar
|
|
46
|
Luo Y, Wu JY, Lu MH, Shi Z, Na N and Di
JM: Carvacrol alleviates prostate cancer cell proliferation,
migration, and invasion through regulation of PI3K/Akt and MAPK
signaling pathways. Oxid Med Cell Longev. 2016:14696932016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dirican A, Atmaca H, Bozkurt E, Erten C,
Karaca B and Uslu R: Novel combination of docetaxel and
thymoquinone induces synergistic cytotoxicity and apoptosis in
DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
Clin Transl Oncol. 17:145–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
